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Background: Sibutramine, used in obesity treatment, has been associated with many neuropsychiatric side effects
including hypomanic and manic episodes. Hypomanic/manic episodes related to sibutramine treatment were earlier
reported in patients who had previous history of bipolar disorder, after sibutramine overdose, after over-the-counter
product illegally containing very high dose of sibutramine, together with psychotic symptoms, in organic patient, or
after interaction of sibutramine with other drugs.
Case presentation: We report the first case of a patient with clear manic episode, after treatment with
recommended dose of sibutramine, without previous history of mood disorders, organic changes or drug
interactions, that was followed by episode of depression.
Conclusion: Minimal recommended dose of sibutramine induced manic episode that was the first manifestation of
bipolar disorder. The manic episode, associated with sibutramine treatment, was induced in a person without
previous history of mood disorders. Potential risks associated with the treatment of obesity using sibutramine warn
physicians to be alert not only to common and cardiovascular but also to psychiatric adverse effects. A careful
assessment of patient’s mental state and detailed psychiatric family history should be done before sibutramine
treatment. In patients with a family history for bipolar disorder the use of even minimal dose of sibutramine should
be contraindicated.
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Sibutramine, used in obesity treatment, is centrally acting
serotonin-, norephiephrine-, and, to a lesser extent,
dopamine- reuptake inhibitor [1]. It works by inducing sa-
tiety and thermogenesis. The anorectic effect of sibutra-
mine and its metabolites is thought to be mediated via α1-
and β1-adrenergic as well as serotoninergic (5-HT2B/2C)
receptors. The thermogenic effect of sibutramine is
thought to be mediated by stimulating β3 adrenoreceptors
in brown adipose tissue [2]. Sibutramine treatment has
been associated with side effects: common (insomnia,
nausea, dry mouth, and constipation), cardiovascular
(increased risk of stroke and heart attack) and neuro-
psychiatric [2,3]. Case reports of neuropsychiatric disor-
ders linked to the use of sibutramine include episodes of* Correspondence: napoleonwas@yahoo.com
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[10], depression with suicidal tendencies [1], delirious
state [11], amnesia [12], and hypomanic or manic episodes
[13-15]. While on sibutramine medication, psychiatric epi-
sodes needed 3 to12 weeks to develop for psychosis, more
than 10 days for panic attacks, more than 2 weeks for deli-
rious and hypomania/mania states, and from 1 day to
1 month for amnesia episodes. During sibutramine treat-
ment manic and hypomanic episodes were earlier
reported in patients who had: recommended-daily-dose of
sibutramine (up to 15 mg/day) and previous history of bi-
polar disorder [13,14], an organic hypomanic episode sec-
ondary to sibutramine-citalopram interaction (10 mg/day
of sibutramine) [15], mixed episode after sibutramine
overdose (30 mg/day) [16], recurrent affective psychosis
after the therapeutic dose of sibutramine [8] or de novo
affective psychosis in relation to sibutramine-sertraline
interaction [7] and after over-the-counter product illegally
containing therapeutic or above the normal range doses ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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[9,17]. A Medline search failed to find any report of
clear manic episode triggered by recommended dose of
sibutramine medication, in person without previous his-
tory of mood disorders, organic brain changes or drug
interactions.Case report
A 23-year-old woman was brought to the psychiatric de-
partment by her mother because of a change in behavior
that appeared four weeks before the submission. At sub-
mission day (sixth week of sibutramine treatment at the
recommended dosage of 10 mg/day), she presented ele-
vated and expansive mood, increased energy and explo-
sive reactions, was talkative and reported racing
thoughts. Her mother stated that daughter had not slept
for the past 4 weeks but felt rested, and stayed up all
night cleaning the house. Daughter speech was rapid
and loud, and it was hard to interrupt her. Mother said
that daughter was out of home overnight on two occa-
sions in the past month, being picked up by police for
public alcohol drinking. It was behavior very unlikely
her usual self. The patient stated that she just wanted to
get out of the house to visit her friends and meet new
interesting people. Following sibutramine withdrawal
and introduction of valproic acid (2000 mg/day), the pa-
tient experienced a remission of manic episode in ap-
proximately 2 weeks.
Six weeks later, she was admitted to the psychiatric de-
partment again with complaints of a depressed mood,
loss of interest and pleasure, and marked psychomotor
retardation. She said that for more than the past 2 weeks
she often stayed in bed all day because of fatigue and
lack of motivation. She felt guilty about the irresponsibil-
ity and excesses of the previous manic episode. She
could not sleep and woke up early morning, stopped eat-
ing and bathing, her ability to think and concentrate
diminished markedly. Before the manic episode, there
was no significant past medical, psychiatric or substance
abuse history. The results of the patient’s physical and
neurological examination, laboratory tests (including
function of thyroid, liver and kidney), magnetic reson-
ance imaging (MRI) of her brain, and ECG did not re-
veal any significant abnormalities. She had a positive
family history for depression in her grandmother and bi-
polar disorder in her aunt. She was diagnosed as having
a bipolar disorder, most recent episode depressed. In the
psychiatric department, valproic acid treatment was
maintained at the dose of 1500 mg/day, and sertraline
100 mg/day was started, with good results. In view of
significant improvement, the patient was discharged
after one month of hospitalization. There were no symp-
toms of mood disorder during 1 year of follow-up.Conclusion
The temporal relationship between sibutramine intake
and onset of behavioral changes as well as the decrease
in manic symptoms with cessation of sibutramine and
initiation of anti-manic pharmacotherapy led us to sus-
pect the role of sibutramine in the pathogenesis of
manic episode. It could be hypothesized that sibutra-
mine may induce mania in predisposed individuals by
acting in a similar way with other selective serotonine
reuptake inhibitors (SSRIs) [14]. In the 1980s sibutra-
mine was initially intended as an antidepressant drug
[3]. In the 2000s antidepressant-associated mania has
been linked to all major antidepressant classes in a sub-
group of 20-40 % of bipolar patients [18,19]. Bipolar
spectrum incorporates classic bipolar disorder (manic +
depressive episode), bipolar II disorder (hypomanic + de-
pressive episode), and bipolar III disorder that is not an
official diagnosis recognized by psychiatric associations.
Although we will not find bipolar III disorder mentioned
in the International Classification of Diseases (ICD-10)
or Diagnostic and Statistical Manual of the American
Psychiatric Association (DSM-IV), psychiatric profes-
sionals use the unofficial diagnosis of bipolar III disorder
to describe patients who have experienced manic or
hypomanic episode due to antidepressant treatment [20].
The serotonin transporter gene is a candidate to be asso-
ciated with antidepressant-associated mania in some
patients [21]. The serotonin transporter gene demon-
strates a polymorphism within the promoter region
(5-HTTLPR) with two allelic forms -the long and the
short variants. Since 5-HTTLPR polymorphism is con-
sidered as a predictor of abnormal response to antide-
pressants in vulnerable to bipolar disorder patients, a
correct diagnosis of bipolarity and detailed family history
for affective disorders should be done before the begin-
ning of sibutramine treatment. It is essential mainly for
short variant of 5-HTTLPR carriers [19]. As chronic
sleep deprivation can precipitate the manic episode, in-
somnia (a very common side-effect of sibutramine)
might exacerbate manic symptoms in our vulnerable pa-
tient. It was also hypothesized that individuals can en-
gage in overeating for the purpose of regulating their
mood [22]. Therefore, bipolar patients may overeat to
“self medicate” their affective symptoms, and suppres-
sion of overeating and/or weight loss might therefore
trigger the onset or exacerbation of the mood symptoms.
It is also possible that the weight loss might also be asso-
ciated with release of toxins, including drugs that might
have mood destabilizing effects [22].
Although the neuropsychiatric side effects of sibutra-
mine have not yet been completely elucidated, there is
accumulating literature on a variety of psychiatric distur-
bances caused by sibutramine. Further studies are
required to clarify the relationship between sibutramine
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Sibutramine, as an antiobesity drug was approved in the
USA in 1997 and in the European Union in 1999, but
recently followed the example of another antiobesity drug
-rimonabant (an inverse agonist for the cannabinoid re-
ceptor CB1) that was removed from all markets in the
European Union [23]. There was concluded that the risks
of cardiovascular complications of sibutramine were
greater than its benefits. Potential risks associated with
the sibutramine treatment of obesity warn physicians to
be alert not only to cardiovascular events but also to psy-
chiatric adverse effects. Therefore a careful assessment of
patient’s mental state together with detailed family psychi-
atric history should be done before beginning sibutramine
treatment. If patients present a first episode of psychosis,
mania, or other psychiatric disorder, they should be inves-
tigated thoroughly while sibutramine is being withheld [3].
It is important to obtain information about vulnerability
of the patient to psychiatric disorders and whether even-
tual symptoms were due to a primary psychiatric disorder
or to a drug-induced episode. In patients with weight gain
while on antipsychotic medications (e.g. olanzapine treat-
ment), sibutramine, if not managed appropriately, could
conceivably exacerbate psychotic episode symptoms or
trigger its relapse. Physicians should also remember that
use of sibutramine is contraindicated not only in patients
with a history of coronary artery disease, heart failure,
arrhythmias, cerebrovascular disease, inadequately con-
trolled hypertension, bulimia/anorexia nervosa, preg-
nancy, lactation, severe renal or liver dysfunction, narrow
angle glaucoma, but also in patients treated with monoa-
mineoxidase inhibitors (MAOIs), selective serotonine re-
uptake inhibitors (SSRIs) or certain migraine drugs as
triptans, because of potential risk of serotonin syndrome.
Thus, a 2-week interval is required after stopping MAIOs
-before treatment with sibutramine, and after stopping
sibutramine -before treatment with MAOIs [3].
All of the abovementioned aspects of sibutramine
treatment require careful weighting, and benefits of
obesity pharmacotherapy must outweigh the risks and
costs. Albert Einstein said: “The devil has put a penalty
on all things we enjoy in life. Either we suffer in health
or we suffer in soul or we get fat”, but patients do not
have to suffer in health or soul when they try to lose fat.
When the patient has a positive family history for bipo-
lar disorder, a change to the other antiobesity drug than
sibutramine may be required (e.g. to orlistat). The
neurobiology of obesity is extremely complex and many
novel potential antiobesity drugs and targets are identi-
fied including those acting on the central pathways as
ciliary neurotrophic factor, melanocortin-4 receptor ago-
nists, ghrelin, neuropeptide Y antagonists, melanin-
concentrating hormone antagonists, or peptide Y [2,3].
However, the most effective long-term weight loss stilldepends on motivation for permanent decrease in en-
ergy intake, improving dietary quality, and increase in
physical activity. Further research should take into con-
sideration the use of a mood stabilizers in prevention of
mood changes in predisposed individuals, before sibutra-
mine treatment. The main conclusion of our case is that
the use of sibutramine (even in minimal recommended
dose) should be contraindicated in patients with a family
history for bipolar disorder.
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